Rayzebio Propels Forward With $418 Million Raised Since Inception To Advance Targeted Radiopharmaceuticals For Cancer
Rayzebio Propels Forward With $418 Million Raised Since Inception To Advance Targeted Radiopharmaceuticals For Cancer
09/13/22, 12:07 PM
Location
san diegoMoney raised
$418 million
RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced a $160 million Series D financing co-led by Viking Global Investors, Sofinnova Investments and Wellington Management. Additional new investors Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital, and an undisclosed global investor also participated, as did RayzeBio’s current investors. With this financing, RayzeBio has now raised $418 million since beginning operations in August 2020.
Company Info
Location
5505 morehouse drive, suite 300
san diego, california, united states
Additional Info
RayzeBio Inc. is now part of Bristol Myers Squibb. Follow our progress delivering breakthrough therapies through our differentiated radiopharmaceutical platform @Bristol Myers Squibb or www.bms.com